Skip to main content

Table 1 Patient characteristics

From: Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma

Characteristic

Training dataset (N = 61)

Testing dataset (N = 25)

P value

External dataset (N = 26)

Age,median (range)years

50(33–74)

51(40–58)

0.970

52(40–74)

FIGO stage, No. (%)

 Ia

18(29.50)

4(16.00)

 

5(19.23)

 Ib

26(42.60)

10(40.00)

 

12(46.15)

 IIa

17(27.90)

11(44.00)

 

9(34.62)

Tumor grade, No. (%)

  

0.085

 

 Well differentiate

14(23.00)

6(24.00)

 

6(23.08)

 Moderately differentiate

29(47.50)

17(68.00)

 

15(57.69)

 Poorly differentiate

18(29.50)

2(8.00)

 

5(19.23)

Depth of cervical stromal tumor invasion, No. (%)

  

0.605

 

  ≥ 1/2

43(70.50)

19(76.00)

 

21(80.77)

 <1/2

18(29.50)

6(24.00)

 

5(19.23)

LVSI, No. (%)

  

0.921

 

 Yes

30(49.20)

12(48.00)

 

15(57.69)

 No

31(50.80)

13(52.00)

 

11(42.31)

COX-2 expression No. (%)

  

0.400

 

 Negative or Weak-Positive

28(45.90)

11(44.00)

 

11(42.31)

 Moderate-Positive

22(36.10)

12(48.00)

 

10(38.46)

 Strong-Positive

11(18.00)

2(8.00)

 

5(19.23)

TNC expression No. (%)

  

0.975

 

 Negative or Weak-Positive

40(65.60)

17(68.00)

 

19 (73.08)

 Moderate-Positive

16(26.20)

6(24.00)

 

6(23.08)

 Strong-Positive

5(8.20)

2(8.00)

 

1(3.85)

  1. FIGO International Federation of Gynecology and Obstetrics, LVSI lymphovascular space invasion, COX-2 cyclooxygenase-2, TNC tenascin-C